In Incyte Corp. v Sun Pharmaceutical Indus., Inc., the Federal Circuit found a PGR petitioner lacked standing to appeal because its “development plans amount to an expression ofintent to create a product that runs a substantial risk of infringement if it is able to clear all development hurdles, secure FDA-approval, and bring its product to market” which…